Takeda logo

Takeda Named Global Top Employer for Eighth Consecutive Year

Takeda Named Global Top Employer for Eighth Consecutive Year


Calendar
January 17, 2025
  • Achieved Global Recognition and Top Employer Certification in 24 Countries from Top Employers Institute
  • Global Recognition Reinforces Commitment to Creating an Exceptional People Experience

Takeda today announced that for the eighth consecutive year, it has received global Top Employer® certification. Takeda is one of just 17 companies that received global recognition, and it also was certified as a Top Employer in 24 countries.

The Top Employers Institute program certifies organisations based on the participation and results of their HR Best Practices Survey. This survey covers 20 topics including people strategy, work environment, talent acquisition, learning, diversity & inclusion, well-being and more. Companies are evaluated on existing policies and practices.

“At Takeda, we are dedicated to delivering life-transforming treatments to patients and recognise that meaningful change is driven by people,” said Jenn Jones, Head of HR for Takeda Oceania. “Their efforts drive our success, and so we are always making improvements to our workplace experience, both here in Australia and globally.”

"We are proud to receive the Top Employer certification for the eighth consecutive year. This recognition underscores our commitment to creating a workplace that supports our people to perform at their best. We believe that by fostering a positive work environment, we can continue to drive innovation and deliver exceptional care to patients across Australia and New Zealand,” said David Pearce, GM Takeda Oceania.

Top Employers Institute CEO David Plink said: “Consistency in a not-so-consistent world? In a time of constant change—where technological, economic, and social shifts are ever-present—exceptional times bring out the best in people and organisations. This year’s Top Employers Certification Programme has showcased this strength, with the certified Top Employers for 2025 demonstrating outstanding dedication to their employees globally. Their consistent commitment to people practices worldwide makes them stand out as an exclusive group who have earned global certification through the Top Employers Programme. We are proud to celebrate these companies and their achievements in 2025.”

Takeda excelled globally in the areas of ethics & integrity, purpose & values, business strategy, employer branding and organization & change. The full list of countries where Takeda was named a Top Employer is below:

  • Asia Pacific: Australia, China, India, Japan, South Korea
  • Europe: Austria, Czech Republic, France, Germany, Ireland, Italy, Poland, Portugal, Slovakia, Spain, Switzerland, United Kingdom
  • Latin America: Argentina, Brazil, Colombia, Mexico
  • Middle East: Israel
  • North America: Canada and United States

To learn more about Top Employers Institute and the Top Employers certification, please visit: https://www.topemployers.comGo to https://www.topemployers.com

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

Media Contacts:

Takeda Oceania Communications

[email protected]

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.